Pharmacokinetics of Telavancin in Normal and Obese Subjects

Phase 1 Completed 32 enrolled University of Illinois at Chicago Theravance Biopharma · collab

NaSingle-groupOpen-label

Summary

The purpose of this study is to characterize plasma and urinary concentrations of telavancin following intravenous administration of a single dose of telavancin in healthy subjects who are normal weight, overweight, and obese.

Timeline

Start: 2016-04
Primary completion: 2016-10
Completion: 2016-10

Publications

Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA. Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02475-17. doi: 10.1128/AAC.02475-17. Print 2018 Apr.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Telavancin	Other / unclassified	500 mg	Intravenous
Subject	Telavancin	Other / unclassified	750 mg	Intravenous
Subject	Telavancin	Other / unclassified	1000 mg	Intravenous

Indications

No indication recorded.